Literature DB >> 10366516

Quality-Adjusted Life Years (QALY) Utility Models under Expected Utility and Rank Dependent Utility Assumptions.

.   

Abstract

Quality-adjusted life years (QALY) utility models are multiattribute utility models of survival duration and health quality. This paper formulates six classes of QALY utility models and axiomatizes these models under expected utility (EU) and rank-dependent utility (RDU) assumptions. The QALY models investigated in this paper include the standard linear QALY model, the power and exponential multiplicative models, and the general multiplicative model. Emphasis is placed on a preference assumption, the zero condition, that greatly simplifies the axiomatizations under EU and RDU assumptions. The RDU axiomatizations of QALY models are generally similar to their EU counterparts, but in some cases, they require modification because linearity in probability is no longer assumed, and rank dependence introduces asymmetries between the domains of better-than-death health states and worse-than-death health states. Copyright 1999 Academic Press.

Year:  1999        PMID: 10366516     DOI: 10.1006/jmps.1999.1256

Source DB:  PubMed          Journal:  J Math Psychol        ISSN: 0022-2496            Impact factor:   2.223


  5 in total

1.  Exponential health utility. A characterization and comments on the contribution by Happich and Muhlbacher.

Authors:  Lars Peter Osterdal
Journal:  Eur J Health Econ       Date:  2004-12

Review 2.  Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases.

Authors:  Jasper M Bos; Philippe Beutels; Lieven Annemans; Maarten J Postma
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 3.  An educational review of the statistical issues in analysing utility data for cost-utility analysis.

Authors:  Rachael Maree Hunter; Gianluca Baio; Thomas Butt; Stephen Morris; Jeff Round; Nick Freemantle
Journal:  Pharmacoeconomics       Date:  2015-04       Impact factor: 4.981

4.  Surgical treatment for adult spinal deformity: projected cost effectiveness at 5-year follow-up.

Authors:  Jamie Terran; Brian J McHugh; Charla R Fischer; Baron Lonner; Daniel Warren; Steven Glassman; Keith Bridwell; Frank Schwab; Virginie Lafage
Journal:  Ochsner J       Date:  2014

5.  A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer.

Authors:  J Wang; Z Zhao; B Barber; B Sherrill; M Peeters; J Wiezorek
Journal:  Br J Cancer       Date:  2011-05-24       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.